Faeth Therapeutics is pioneering multi-node inhibition of the PAM (PI3K/AKT/mTOR) pathway — the most frequently altered oncogenic pathway in cancer. Our lead candidate PIKTOR is an all-oral combination that is designed to achieve deeper pathway suppression with greater tolerability by targeting multiple nodes simultaneously.
Calendar
–
View all events & presentations
Events.
Nov
09
2026
Virtual Event: PIK-201 Phase 2 Data in Advanced Endometrial Cancer
Oct
06
2026
Virtual KOL Event: Multi-Nodal Inhibition for the Treatment of Endometrial Cancer
Latest
–
View all news
News and updates.
Nov 16 2026
Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer
Faeth will sponsor and conduct a Phase 1b/2 study evaluating PIKTOR, its investigational all-oral combination of serabelisib and sapanisertib, in combination with the investigational medicine giredestrant Faeth retains all rights to PIKTOR; under the agreement, Roche will supply giredestrant for
Read More
Nov 11 2026
Faeth Therapeutics to Participate in Upcoming November Investor Conferences
AUSTIN, Texas --(BUSINESS WIRE)--Nov. 11, 2026-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that management will participate in the following upcoming investor
Read More
Nov 09 2026
Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer
Confirmed Objective Response Rate (ORR) of 33% in efficacy-evaluable patients (12 of 36), and a disease control rate (DCR) of 83% Among patients with a PIK3CA mutation, the confirmed ORR was 44% (7 of 16) Preliminary Kaplan-Meier estimated median progression-free survival (mPFS) of 7.4 months, with
Read More
Nov 06 2026
Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026
AUSTIN, Texas --(BUSINESS WIRE)--Nov. 6, 2026-- Faeth Therapeutics (Nasdaq: FTH), a clinical- stage biotechnology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual event on Monday, November 9 at 8:00 AM ET to
Read More
Nov 05 2026
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, Texas --(BUSINESS WIRE)--Nov. 5, 2026-- Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted three new employees options to purchase an aggregate of 68,000 shares of the Company’s common stock in connection with their
Read More